Literature DB >> 19226205

Effect of VEGF treatment on the blood-spinal cord barrier permeability in experimental spinal cord injury: dynamic contrast-enhanced magnetic resonance imaging.

Chirag B Patel1, David M Cohen, Pallavi Ahobila-Vajjula, Laura M Sundberg, Tessy Chacko, Ponnada A Narayana.   

Abstract

Compromised blood-spinal cord barrier (BSCB) is a factor in the outcome following traumatic spinal cord injury (SCI). Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis and vascular permeability. The role of VEGF in SCI is controversial. Relatively little is known about the spatial and temporal changes in the BSCB permeability following administration of VEGF in experimental SCI. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies were performed to noninvasively follow spatial and temporal changes in the BSCB permeability following acute administration of VEGF in experimental SCI over a post-injury period of 56 days. The DCE-MRI data was analyzed using a two-compartment pharmacokinetic model. Animals were assessed for open field locomotion using the Basso-Beattie-Bresnahan score. These studies demonstrate that the BSCB permeability was greater at all time points in the VEGF-treated animals compared to saline controls, most significantly in the epicenter region of injury. Although a significant temporal reduction in the BSCB permeability was observed in the VEGF-treated animals, BSCB permeability remained elevated even during the chronic phase. VEGF treatment resulted in earlier improvement in locomotor ability during the chronic phase of SCI. This study suggests a beneficial role of acutely administered VEGF in hastening neurobehavioral recovery after SCI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226205      PMCID: PMC2857512          DOI: 10.1089/neu.2008.0860

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  63 in total

1.  Experimental modeling of spinal cord injury: characterization of a force-defined injury device.

Authors:  Stephen W Scheff; Alexander G Rabchevsky; Isabella Fugaccia; John A Main; James E Lumpp
Journal:  J Neurotrauma       Date:  2003-02       Impact factor: 5.269

Review 2.  VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.

Authors:  Erik Storkebaum; Diether Lambrechts; Peter Carmeliet
Journal:  Bioessays       Date:  2004-09       Impact factor: 4.345

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  In vivo assessment of blood-spinal cord barrier permeability: serial dynamic contrast enhanced MRI of spinal cord injury.

Authors:  Mehmet Bilgen; Bulent Dogan; Ponnada A Narayana
Journal:  Magn Reson Imaging       Date:  2002-05       Impact factor: 2.546

5.  Morphometric analysis of a model of spinal cord injury in guinea pigs, with behavioral evidence of delayed secondary pathology.

Authors:  A R Blight
Journal:  J Neurol Sci       Date:  1991-06       Impact factor: 3.181

6.  Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression.

Authors:  Yonghua Zhu; Kunlin Jin; Xiao Ou Mao; David A Greenberg
Journal:  FASEB J       Date:  2003-02       Impact factor: 5.191

7.  Microangiographic study of spinal cord injury and myelopathy.

Authors:  H Shingu; I Kimura; Y Nasu; A Shiotani; M Oh-hama; A Hijioka; J Tanaka
Journal:  Paraplegia       Date:  1989-06

8.  Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury.

Authors:  J Widenfalk; A Lipson; M Jubran; C Hofstetter; T Ebendal; Y Cao; L Olson
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo.

Authors:  Kunlin Jin; Yonghua Zhu; Yunjuan Sun; Xiao Ou Mao; Lin Xie; David A Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

10.  VEGF165 therapy exacerbates secondary damage following spinal cord injury.

Authors:  Richard L Benton; Scott R Whittemore
Journal:  Neurochem Res       Date:  2003-11       Impact factor: 3.996

View more
  19 in total

1.  Neuroprotective effect of bone marrow stromal cell combination with atorvastatin in rat model of spinal cord injury.

Authors:  Fang Li; Dan Fei; Libo Sun; Sixun Zhang; Yue Yuan; Li Zhang; Kuiming Zhao; Rui Li; Yanbing Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Targeting microvasculature for neuroprotection after SCI.

Authors:  Janelle M Fassbender; Scott R Whittemore; Theo Hagg
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Kristan H Cleveland; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

Review 4.  Investigating the blood-spinal cord barrier in preclinical models: a systematic review of in vivo imaging techniques.

Authors:  Joshua Bakhsheshian; Ben A Strickland; William J Mack; Berislav V Zlokovic
Journal:  Spinal Cord       Date:  2021-03-19       Impact factor: 2.772

5.  Rescuing vasculature with intravenous angiopoietin-1 and alpha v beta 3 integrin peptide is protective after spinal cord injury.

Authors:  Shu Han; Sheila A Arnold; Srinivas D Sithu; Edward T Mahoney; Justin T Geralds; Phuong Tran; Richard L Benton; Melissa A Maddie; Stanley E D'Souza; Scott R Whittemore; Theo Hagg
Journal:  Brain       Date:  2010-04       Impact factor: 13.501

6.  Batroxobin protects against spinal cord injury in rats by promoting the expression of vascular endothelial growth factor to reduce apoptosis.

Authors:  Hui Yu; Bin Lin; Yongzhi He; Wenbin Zhang; Yang Xu
Journal:  Exp Ther Med       Date:  2015-03-17       Impact factor: 2.447

7.  Effect of vascular endothelial growth factor treatment in experimental traumatic spinal cord injury: in vivo longitudinal assessment.

Authors:  Laura M Sundberg; Juan J Herrera; Ponnada A Narayana
Journal:  J Neurotrauma       Date:  2011-03-24       Impact factor: 5.269

Review 8.  Biomaterial strategies for limiting the impact of secondary events following spinal cord injury.

Authors:  Trevor R Ham; Nic D Leipzig
Journal:  Biomed Mater       Date:  2018-02-08       Impact factor: 3.715

9.  Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury.

Authors:  Xiaoxin Cheng; Yiyan Zheng; Ping Bu; Xiangbei Qi; Chunling Fan; Fengqiao Li; Dong H Kim; Qilin Cao
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

10.  The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.

Authors:  Jennifer N Dulin; Meredith L Moore; Raymond J Grill
Journal:  J Neurotrauma       Date:  2013-01-23       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.